3 Reasons You Should Buy SENS Stock Today

If you’re looking for an outstanding stock to invest in, here are three reasons why you should consider SENS stock.

SENS stock is an exciting investment opportunity for your portfolio.

It’s a high-growth company with a strong business model and a low share price.

And it’s positioned to take advantage of the inevitable aging population.

3 Reasons You Should Buy SENS Stock Today

SENS (Adaptimmune Therapeutics plc) stock is an exciting opportunity for your portfolio.

The company is focused on the development of gene therapy for cancer and infectious disease. The company’s lead drug candidate is called poziotinib, which is in a phase 3 trial to treat late-stage colon cancer. In a phase 1 study combined with chemotherapy, the drug was shown to extend overall survival for patients with late-stage liver cancer.

SENS’ second pipeline candidate is SPEAR T-cell receptor T-cell immunotherapy, which is an anti-cancer immunotherapy.

Last year, it reported positive phase 2 data in pancreatic cancer. At the same time, the company’s phase 1 trial of SPEAR T-cell immunotherapy for melanoma showed promising results.

SENS stock is an exciting investment opportunity for your portfolio

The biggest reason that SENS stock is so exciting is its dividend. It currently pays a monthly dividend of 1 cent per share. This translates to a dividend yield of 8.11%, and it’s increased its dividend every quarter since 2013. In the previous quarter, SENS raised its dividend to 1 cent per share.

In the past, the Board of Directors has authorized SENS to increase its monthly dividend by 20% or more. And it’s indicated it would consider this if SENS’ free cash flow, or FCF, is sufficiently strong.

Even with a current yield of 8.11%, SENS is undervalued. Because of this, many consider SENS one of the best stocks to buy now. In fact, as a micro-cap company, its valuation is low. On a price-to-sales (P/S) basis, SENS stock is trading at a P/S ratio of only 0.

It’s a high-growth company with a strong business model and a low share price

I think SENS is a great investment opportunity because it’s in the early innings of its growth phase.

Yes, it’s still a small-cap company. In terms of sales, it ranks 198th on the Fortune 500.

But sales are growing rapidly, while earnings are on the brink of exploding.

Revenue rose 5% annually in 2017, and it has the opportunity to improve its operating margins. If that happens, operating profits should climb as well.

There’s also a potential catalyst on the horizon: the legalization of recreational marijuana in Canada. The Canadian government is expected to make this decision in the Spring of 2018. A decision against legalization could send pot stocks plummeting.

And it’s positioned to take advantage of the inevitable aging population.

The healthcare market is undergoing fundamental change.

Aging populations are creating huge demand for healthcare. Moreover, a huge amount of research is pointing to chronic diseases as a major factor driving health care spending. The healthcare market is changing fast, with Amazon getting into the business of pharmacy distribution. And drug companies are discovering the true value of a digital record, with pharma giant Novartis (NYSE: NVS ) trading at a discount to its fair value as a result.

All of this points to big opportunities for SENS stock. It’s a high-growth company with a proven business model.